US5501956A - Polyredox couples in analyte determinations - Google Patents
Polyredox couples in analyte determinations Download PDFInfo
- Publication number
- US5501956A US5501956A US08/185,730 US18573094A US5501956A US 5501956 A US5501956 A US 5501956A US 18573094 A US18573094 A US 18573094A US 5501956 A US5501956 A US 5501956A
- Authority
- US
- United States
- Prior art keywords
- assay medium
- oxidase
- redox couple
- ruthenium
- hydrogen peroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012491 analyte Substances 0.000 title description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229910052751 metal Inorganic materials 0.000 claims abstract description 25
- 239000002184 metal Substances 0.000 claims abstract description 25
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910052707 ruthenium Inorganic materials 0.000 claims abstract description 18
- 239000000758 substrate Substances 0.000 claims abstract description 17
- JTNGEYANGCBZLK-UHFFFAOYSA-N 1h-indol-3-yl dihydrogen phosphate Chemical compound C1=CC=C2C(OP(O)(=O)O)=CNC2=C1 JTNGEYANGCBZLK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910000510 noble metal Inorganic materials 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 27
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 20
- 102000004316 Oxidoreductases Human genes 0.000 claims description 14
- 108090000854 Oxidoreductases Proteins 0.000 claims description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 14
- 102000003992 Peroxidases Human genes 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 229910052742 iron Inorganic materials 0.000 claims description 10
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 9
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 claims description 9
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 8
- 238000006911 enzymatic reaction Methods 0.000 claims description 8
- -1 indoxyl ester Chemical class 0.000 claims description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 7
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 claims description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- 102000004157 Hydrolases Human genes 0.000 claims description 6
- 108090000604 Hydrolases Proteins 0.000 claims description 6
- 238000006479 redox reaction Methods 0.000 claims description 5
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 claims description 4
- 108010089254 Cholesterol oxidase Proteins 0.000 claims description 4
- UETZVSHORCDDTH-UHFFFAOYSA-N iron(2+);hexacyanide Chemical group [Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] UETZVSHORCDDTH-UHFFFAOYSA-N 0.000 claims description 4
- 108010015776 Glucose oxidase Proteins 0.000 claims description 3
- 239000004366 Glucose oxidase Substances 0.000 claims description 3
- 229940116332 glucose oxidase Drugs 0.000 claims description 3
- 235000019420 glucose oxidase Nutrition 0.000 claims description 3
- 239000012911 assay medium Substances 0.000 claims 16
- NHWGPUVJQFTOQX-UHFFFAOYSA-N ethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethyl-methylamino]ethyl]-dimethylazanium Chemical compound CC[N+](C)(C)CCN(C)CC[N+](C)(C)CC NHWGPUVJQFTOQX-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 41
- 108090000790 Enzymes Proteins 0.000 abstract description 41
- 239000004065 semiconductor Substances 0.000 abstract description 5
- 229940088598 enzyme Drugs 0.000 description 40
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 239000012528 membrane Substances 0.000 description 14
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 229910052710 silicon Inorganic materials 0.000 description 10
- 239000010703 silicon Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 9
- 229910052737 gold Inorganic materials 0.000 description 9
- 239000010931 gold Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 229910052581 Si3N4 Inorganic materials 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 4
- 229910052814 silicon oxide Inorganic materials 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 235000012431 wafers Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000005530 etching Methods 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 108700020962 Peroxidase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710116602 DNA-Binding protein G5P Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 241001363516 Plusia festucae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710162453 Replication factor A Proteins 0.000 description 1
- 101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 1
- 101710176276 SSB protein Proteins 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004082 amperometric method Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- MROCJMGDEKINLD-UHFFFAOYSA-N dichlorosilane Chemical compound Cl[SiH2]Cl MROCJMGDEKINLD-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- UPCIBFUJJLCOQG-UHFFFAOYSA-L ethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethyl-methylamino]ethyl]-dimethylazanium;dibromide Chemical compound [Br-].[Br-].CC[N+](C)(C)CCN(C)CC[N+](C)(C)CC UPCIBFUJJLCOQG-UHFFFAOYSA-L 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- JLKXXDAJGKKSNK-UHFFFAOYSA-N perchloric acid;pyridine Chemical compound OCl(=O)(=O)=O.C1=CC=NC=C1 JLKXXDAJGKKSNK-UHFFFAOYSA-N 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 238000004313 potentiometry Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- XJKVPKYVPCWHFO-UHFFFAOYSA-N silicon;hydrate Chemical compound O.[Si] XJKVPKYVPCWHFO-UHFFFAOYSA-N 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2326/00—Chromogens for determinations of oxidoreductase enzymes
- C12Q2326/10—Benzidines
- C12Q2326/12—3,3',5,5'-Tetramethylbenzidine, i.e. TMB
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
- C12Q2334/50—Indoles
- C12Q2334/52—5-Bromo-4-chloro-3-indolyl, i.e. BCI
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/817—Enzyme or microbe electrode
Definitions
- the field of this invention is the use of bioensors to detect redox reactions involving enzymes.
- assays involving the detection of enzyme activity either for measuring enzyme substrate, enzyme, or the enzyme as a label have depended upon colorometric or fluorimetric detection.
- colorometric or fluorimetric detection there has been a continuous and expanding interest in electrical detection using either amperometric or potentiometric methods. These methods require a redox couple which can be detected at an electrode.
- compositions must be developed which allow for the transport of electrons from the enzyme or a product of the enzyme.
- the various materials which are employed must not interfere with each other, so that neither the enzyme reaction, nor the transfer of electrons to the electrode, are adversely affected.
- the analyte is present in very low concentration, it is important that the individual reaction related to the amount of analyte be very rapid, desirably diffusion controlled. In this circumstance, there will be a rapid response for each enzymatic event.
- compositions which may be used in the electrical detection of enzymatic reactions, by providing for rapid and efficient transfer of electrons to an electrical sensor as a result of enzymatic reaction.
- compositions are provided for determining enzymatic activity in a medium employing an organic substrate coupled with an inorganic redox couple for efficient transfer to a metal electrode.
- Methods and compositions are provided for detecting enzymatic reactions employing a metal electrode.
- the methods employ a combination of reagents, where the first reagent provides for a rapid efficient reaction with the enzyme to produce a product capable of reacting with the second reagent, where the second reagent may be determined amperometrically or potentiometrically.
- the method may involve direct detection of the enzyme, use of an enzyme as a label for detection of ligands, or use of an enzyme to detect enzyme substrate.
- the enzymes to be detected are hydrolases, particularly phosphatases, or oxidoreductases, particularly peroxidases, which may be used by themselves or in conjunction with oxidases.
- the oxidases can produce a product, particularly hydrogen peroxide, with which the peroxidase may react to produce another product which reacts with the second reagent.
- Oxidases which may be coupled with the peroxidase include glucose oxidase, xanthine oxidase, uricase, cholesterol oxidase, and the like.
- the hydrolases can provide hydrolysis of indoxyl esters,-where the acid group may be organic or inorganic, including carboxylates, phosphates, sulfates, etc., or indoxyl glycosidyl ethers, such as ⁇ -galactosidyl, ⁇ -glucosidyl, etc.
- the second reagent is an inorganic redox couple, normally employing an iron or ruthenium couple.
- the iron may be in any convenient form, particularly coordinated, such as with hexacyanoferrate, e.g. ferroor ferricyanide, ferrocene, or other stable form of iron, capable of undergoing one electron transfer.
- the ruthenium will also be coordinated with a variety of ligands, particularly nitrogen ligands, such as pyridine, substituted pyridines, bis-pyridines, pyridine, amino, substituted amino, or the like.
- the ruthenium preferably will be employed in the divalent state, coordinated with 5 NH 3 ligands and 1 pyridine ligand.
- metal electrodes may be employed, particularly inert or noble metal electrodes, such as gold, rhodium, platinum, etc.
- the metal electrode may be used in relation to the semiconductor electrode as is described in application Ser. No. 072,168, filed Jul. 10, 1987, which disclosure is incorporated herein by reference.
- the first reagent will be selected so as to be able to react rapidly and efficiently with the enzyme to produce a product which will have an electromotive potential so as to be capable of reacting with the second reagent.
- the first and second reagents are related in that the electromotive potential of the product of the enzymatic reaction must be at a higher potential than the electromotive potential for the inorganic redox couple.
- benzidine or benzidine derivatives can be employed as the first reagent with advantage, where the benzidine will usually be not more than about 30 carbon atoms, usually not more than about 20 carbon atoms, and may have from 0 to 4, usually from 0 to 2 other heteroatoms as substituents, where the heteroatoms will usually be oxygen or nitrogen, normally present as oxy, oxo or amino, where the oxygen and nitrogen may be substituted with hydrogen or alkyl of from 1 to 3, usually from 1 to 2 carbon atoms.
- substituents include methyl, ethyl, hydroxyl, methoxy, methylamino, etc.
- Indoxyl esters will have the ester group at the 3 position and may be otherwise substituted or unsubstituted, usually unsubstituted, where substituents may be alkyl of from 1 to 3 carbon atoms, oxy of from 0 to 3 carbon atoms, amino of from 0 to 3 carbon atoms, or halogen, where the ethers and substituted amino groups will be substituted by alkyl of from 1 to 3 carbon atoms, usually of from 1 to 2 carbon atoms.
- Halogen substituents may be chlorine, fluorine, or bromine groups, usually 1 to 3, and preferably 2 groups, per indoxyl molecule.
- esters may be employed, which include phosphate, acetate, lactate, sulfate, or the like, or glycosidyl ethers.
- the enzyme concentration may be varied widely, depending upon the sample. Usually, the enzyme will be present in from about 0 to 1 ⁇ g, more usually from about 0 to 10 ng. In addition, this will vary depending upon whether a peroxidase or hydrolase is involved, with the peroxidase being from about 0.1 pg to 10 ng, while the hydrolase will generally be from about 1 pg to 100 ng.
- the benzidine compound will usually be present in about 50 ⁇ M to 1 mM, more usually in 100 to 400 ⁇ M.
- the amount of benzidine will be selected so as to be non-rate limiting, so as to provide substantially a V max .
- the indoxyl compound will also be present in non-limiting amounts generally being present in 0.1 to 2 mM.
- the inorganic redox couple generally will be at a concentration in the range of about 1.0 to 1000 ⁇ M, more usually from about 10 to 200 ⁇ M.
- the solution will be buffered to optimize substantially the enzymatic activity, generally having a pH in the range of about 4 to 12, more usually from about 5.5 to 10 depending upon the pH optimum of the enzyme with the substrates employed.
- Various buffers may be employed, which include tris-(hydroxymethyl) methylamine (Tris), phosphate, borate, or the like, usually employing a buffer suitable for the particular enzyme system.
- the various components may be brought together in an appropriately buffered medium in contact with the metal electrode and the rate of change of redox potential in the medium determined.
- the various reagents may be brought together, where binding of the complementary specific binding pair member to the enzyme conjugate results in a change in enzymatic activity. Thus, in this instance, one need not separate the bound from free enzyme conjugate.
- the subject reagents may be added to either the surface bound enzyme or to the separated supernatant for determination of enzymatic activity. Enzymatic activity is then monitored with a metal electrode in accordance with the subject invention.
- Illustrative of the subject method is the determination of cholesterol, where the cholesterol may be present in a variety of forms, such as HDL, LDL, VLDL or uncomplexed.
- the cholesterol serves as a substrate for cholesterol oxidase to form hydrogen peroxide, which acts as a substrate for horseradish peroxidase.
- the metal electrode may be any type of metal electrode, wire, wafer, grid, or the like. Of particular interest in the subject invention is the use of a metal electrode which is in electrostatic proximity contact with a semiconductor. This device is described in U.S. application Ser. No. 072,196, filed Jul. 10, 1987, whose disclosure is incorporated herein by reference.
- the apparatus of U.S. Pat. No. 4,591,550 also may be used where such device is modified by affixing to the insulating surface a thin metal film to serve as the metal electrode, so that a plurality of assays may be carried out, where each of the metal electrodes bound to the insulating surface are insulated one from the other. Any means of insulation may be used such as, separating the sample solutions associated with each of the metal electrodes with dividers or using gelled samples which are insulated one from the other, or the like.
- the metal electrode will be present on an insulating layer, e.g. silicon oxide or silicon oxynitride with silicon, of about 0.1 to 10 mm thickness.
- the metal electrode will generally have a surface area of about 0.1 to 5 mm 2 and about 0.1 to 1000 ⁇ thickness.
- the electrode may be electrodeposited or affixed with an adhesive which is stable under the conditions to which it is subjected.
- the electrode may be 0.5 ⁇ of gold over 300 Angstroms of chromium over 1000 Angstroms of silicon nitride over 300 Angstroms of silicon oxide over n-type silicon. Any surface of the semiconductor which is exposed to the medium will be protected with an insulating coat, e.g. 1000 Angstroms silicon nitride over 100 Angstroms of silicon oxide.
- the gold layer of about 4.2 mm diameter was placed on a 2.5 mm ⁇ 5.0 mm rectangular silicon chip which is positioned in a reading chamber containing a platinum controlling electrode and an Ag/AgCl reference electrode.
- a membrane with the enzyme of interest bound to it or included in it is positioned over the gold electrode and a plastic plunger is pressed against the membrane to restrict diffusion of reagents from the localized environment of the membrane.
- the silicon chip is fabricated from a 4-inch diameter wafer of N ⁇ 100> silicon of approximately 10 to 15 ohm-cm resistivity.
- the insulator is composed of approximately 340 Angstroms of silicon oxide adjacent to the silicon and overlaid with 1000 Angstroms of silicon nitride deposited by chemical vapor deposition from a reaction of dichlorosilane and ammonia at about 800° C. in a low pressure chamber.
- the wafers are subsequently annealed in a hydrogen ambient at 1050° C. for 1 hour.
- the ohmic contact to the silicon chip is made by evaporating approximately 0.5 ⁇ of gold--1% arsenic onto the (bare) etched back surface of a silicon wafer, etching away the gold from regions where light penetration is desired and then alloying the gold into the silicon at 450° C.
- the sensing gold layer next is deposited over the silicon nitride insulating layer by evaporation in a low pressure chamber of first 300 Angstroms of chromium followed by 5000 Angstroms of gold.
- the 4.2 mm circles are then formed by protection with a positive photoresist followed by etching first the gold and then the chromium by means of standard metal-etching techniques.
- TMB tetramethylbenzidine
- peroxidase buffer 0.1 M NaAcetate, 1 mM EDTA, 7.5% ethanol, pH 5.5;
- a redox solution was-prepared comprising TMB 200 ⁇ M, Ruthenium + 2 pentaamine pyridine 25 ⁇ M, H 2 O 2 , 250 ⁇ M, in peroxidase buffer. Concentrations of horseradish peroxidase on a nitrocellulose support were introduced into the chamber and readings taken by employing a sweep -0.5 to -1.5 volts, gain 16, sweep time 0.4 sec. At 800 pg HRP, the observed result was -3046 ⁇ V/s, at 91 pg, -1784 ⁇ V/s, at 6 pg, and -327 ⁇ V/s at 0 ng.
- a solution was prepared of N. meningitidis (4 ⁇ 10 9 cells/ml).
- a monoclonal antibody-HRP conjugate was prepared and employed in 1:200 dilution in 40% fetal bovine serum (FBS).
- FBS fetal bovine serum
- the membrane filter polycarbonate
- the membrane filter had a 0.2 ⁇ m pore 0.2 ml of sample containing varying concentrations of cells was filtered onto the filter followed by incubation with 50 ⁇ l of conjugate, after which time the filter was washed 2 ⁇ with PBS and 1 ⁇ with NaCl (0.9%)-Tween-20 (0.05%).
- the substrate buffer 0.1 M NaAc, 1 mM EDTA, 5% ethanol, pH 5.5, 0.1% Triton X-100
- TMB 200 ⁇ M
- ferrocyanide 100 ⁇ M
- hydrogen peroxide 250 ⁇ M
- ferri-/ferrocyanide was used as the inorganic redox pair in conjunction with TMB.
- the reaction solution was 10 ⁇ M in potassium ferrocyanide, 0.1 M NaAcetate, pH 5.5, 1 mM EDTA, 0.1% Triton X-100, 5% ethanol, 250 ⁇ M hydrogen peroxide, 200 ⁇ M TMB..
- the HRP conjugate (Lot No. 7-6-87A) was diluted 1:200 in 40% FBS and a N. meningitidis medium (4 ⁇ 10 9 cells/ml in PBS-Tween-20) was employed.
- the cell medium (0.2 ml) was filtered through a 0.2 ⁇ m pore polycarbonate membrane, followed by contacting the membrane for 10 min with 50 ⁇ l of the conjugate, followed by washing once with PBS and once with water.
- ferrocyanide can be used in a sensitive method for detection of organisms through a redox couple.
- Genetran is a positively-charged nylon membrane.
- the membrane was washed using 5% Triton in PBS, pH 7.0, 4 ⁇ 200 ⁇ l. Heat denatured single-stranded calf thymus DNA in deionized water (50 ⁇ l) was added to the membrane.
- SSB-HRP conjugate solution (single-stranded DNA binding protein was coupled using maleimide crosslinking chemistry to thiolated HRP) was diluted 1:15,000 in 0.2% BSA, PBS, 0.05% Tween-20, and 300 ⁇ l of the solution perfused through the membrane using a peristaltic pump, the filtration requiring 3-4 min. The membrane was then washed 3 ⁇ 200 ⁇ l with 5% Triton X-100 in PBS, followed by 3 ⁇ 200 ⁇ l in peroxidase buffer.
- the membrane was then introduced into a compartment which contained the substrate solution comprising 25 ⁇ M of Ru +2 chelate (same as previous example), 200 ⁇ M TMB, and 250 ⁇ M hydrogen peroxide in the previously described buffer.
- the voltage change was +262 ⁇ V/s, while at 150 pg, the voltage change was -63, at 600 pg, -2474, and at 2500 pg, - 16000.
- the negative control gave a voltage change of 150 ⁇ V/s, at +150 pg DNA, -312, at 600 pg DNA, -3116, and at 2500 pg DNA, -19268.
- the apparatus employed was a redox sensor, which used a gold spot on silicon water for the metal electrode as described in Example 1.
- the following reagents were employed:
- the assay was based on using alkaline phosphotase as the enzyme, and the hydrolysis of indoxyl phosphate to indoxal.
- Indoxal is coupled to the inorganic redox component to generate a potentiometric signal.
- the procedure employed was to add 10 ⁇ l of alkaline phosphatase solution or buffer to 1 ml of substrate containing 1 mM indoxyl phosphate, 1 mM ferricyanide and 0.5 mM ferrocyanide in 0.2 M Tris buffer, 1 mM magnesium acetate, 0.05% sodium azide, pH 10.3. This solution was quickly mixed and added to the measurement compartment. Measurements were made every 0.18 min.
- the buffer alone gave a +6.6 ⁇ V/s rate.
- the addition of BSA carrier protein (2%) further increased the background rate to +16 ⁇ V/s.
- Increasing amounts of enzyme were added to the measuring compartment, starting at 7.8 ng/ml as the-concentration in the cell and increasing to 124 ng/ml.
- the reaction rate change in potential ( ⁇ V/s) voltage, was linear in the first 2 minutes of measurement.
- the reaction rate accelerated as the ferricyanide was consumed, which occurred at the two highest enzyme levels tested, 124 and 250 ng/ml.
- the reaction rate was proportional to enzyme concentration from 7.8 to 250 ng/ml, a linear regression analysis gave a R 2 value of 0.997.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Enzyme or substrate determinations can be achieved by employing an organic second substrate, which produces a product which may be coupled with a metal inorganic redox couple capable of interacting with and affecting the potential of a metal electrode on a semiconductor surface. Particularly, hydrogen peroxide or indoxyl phosphate are coupled with iron- or ruthenium-containing ionic redox couples for determination with a noble metal electrode.
Description
This is a continuation of application Ser. No. 07/952,465 filed Sep. 28, 1992, now abandoned which is a continuation of application Ser. No. 07/497,988, filed Mar. 23, 1990 now abandoned.
The field of this invention is the use of bioensors to detect redox reactions involving enzymes.
For the most part, assays involving the detection of enzyme activity, either for measuring enzyme substrate, enzyme, or the enzyme as a label have depended upon colorometric or fluorimetric detection. However, there has been a continuous and expanding interest in electrical detection using either amperometric or potentiometric methods. These methods require a redox couple which can be detected at an electrode.
There are many constraints in developing a diagnostic system. Compositions must be developed which allow for the transport of electrons from the enzyme or a product of the enzyme. The various materials which are employed must not interfere with each other, so that neither the enzyme reaction, nor the transfer of electrons to the electrode, are adversely affected. Because in many instances the analyte is present in very low concentration, it is important that the individual reaction related to the amount of analyte be very rapid, desirably diffusion controlled. In this circumstance, there will be a rapid response for each enzymatic event.
It is therefore of interest to devise compositions which may be used in the electrical detection of enzymatic reactions, by providing for rapid and efficient transfer of electrons to an electrical sensor as a result of enzymatic reaction.
Frew and Mill, Anal. Chem. (1987) 59:933A 944A, provide a review of electrochemical biosensors. Josephy et al., J. Biol. Chem. (1982) 257:3669-3675 describe the use of tetramethylbenzidine as a horse radish peroxidase substrate. References of interest employing biosensors in enzyme immunoassays include Heineman et al., Anal. Proc. (1987) 24:324-325; Alwis and Wilson, Anal. Chem. (1987) 59:2786-2789; Gyss and Boutdillon, Anal. Chem. (1987) 59:2350-2355; Sayo et al., J. of Chromat. (1987) 417:129-134; Lunte et al., "Immunoassay by HPLC and Flow Injection Analysis with Electrochemical Detection" In Proceedings of the Symposium on Electrochemical Sensors for Biomedical Applications, ed. Li, Vol. 86-14, Electrochemical Soc., Inc., N.J., 1986, pp. 129-138; Wehmeyer et al., Anal. Chem. (1986) 58:135-139; Janata, Anal. Proc. (1987) 24:326-328; Weetall and Hotaling, Biosensors (1987) 3:57-63; Davis, Biosensors (1986) 2:101-124; and EPA 85/114836.3.
Compositions are provided for determining enzymatic activity in a medium employing an organic substrate coupled with an inorganic redox couple for efficient transfer to a metal electrode.
Methods and compositions are provided for detecting enzymatic reactions employing a metal electrode. The methods employ a combination of reagents, where the first reagent provides for a rapid efficient reaction with the enzyme to produce a product capable of reacting with the second reagent, where the second reagent may be determined amperometrically or potentiometrically. The method may involve direct detection of the enzyme, use of an enzyme as a label for detection of ligands, or use of an enzyme to detect enzyme substrate.
The enzymes to be detected are hydrolases, particularly phosphatases, or oxidoreductases, particularly peroxidases, which may be used by themselves or in conjunction with oxidases. The oxidases can produce a product, particularly hydrogen peroxide, with which the peroxidase may react to produce another product which reacts with the second reagent. Oxidases which may be coupled with the peroxidase include glucose oxidase, xanthine oxidase, uricase, cholesterol oxidase, and the like.
The hydrolases, particularly esterases or saccharidases, such as β-galactosidase, can provide hydrolysis of indoxyl esters,-where the acid group may be organic or inorganic, including carboxylates, phosphates, sulfates, etc., or indoxyl glycosidyl ethers, such as β-galactosidyl, β-glucosidyl, etc.
The second reagent is an inorganic redox couple, normally employing an iron or ruthenium couple. The iron may be in any convenient form, particularly coordinated, such as with hexacyanoferrate, e.g. ferroor ferricyanide, ferrocene, or other stable form of iron, capable of undergoing one electron transfer. The ruthenium will also be coordinated with a variety of ligands, particularly nitrogen ligands, such as pyridine, substituted pyridines, bis-pyridines, pyridine, amino, substituted amino, or the like. The ruthenium preferably will be employed in the divalent state, coordinated with 5 NH3 ligands and 1 pyridine ligand.
Various metal electrodes may be employed, particularly inert or noble metal electrodes, such as gold, rhodium, platinum, etc. As will be discussed, the metal electrode may be used in relation to the semiconductor electrode as is described in application Ser. No. 072,168, filed Jul. 10, 1987, which disclosure is incorporated herein by reference.
The first reagent will be selected so as to be able to react rapidly and efficiently with the enzyme to produce a product which will have an electromotive potential so as to be capable of reacting with the second reagent. Thus, the first and second reagents are related in that the electromotive potential of the product of the enzymatic reaction must be at a higher potential than the electromotive potential for the inorganic redox couple.
For use with peroxidases, benzidine or benzidine derivatives can be employed as the first reagent with advantage, where the benzidine will usually be not more than about 30 carbon atoms, usually not more than about 20 carbon atoms, and may have from 0 to 4, usually from 0 to 2 other heteroatoms as substituents, where the heteroatoms will usually be oxygen or nitrogen, normally present as oxy, oxo or amino, where the oxygen and nitrogen may be substituted with hydrogen or alkyl of from 1 to 3, usually from 1 to 2 carbon atoms. Generally, there will not be more than 4 substituents bonded to annular carbon atoms, usually not more than 2 substituents bonded to annular carbon atoms, other than the amino groups of the benzidine. Illustrative substituents include methyl, ethyl, hydroxyl, methoxy, methylamino, etc.
Indoxyl esters will have the ester group at the 3 position and may be otherwise substituted or unsubstituted, usually unsubstituted, where substituents may be alkyl of from 1 to 3 carbon atoms, oxy of from 0 to 3 carbon atoms, amino of from 0 to 3 carbon atoms, or halogen, where the ethers and substituted amino groups will be substituted by alkyl of from 1 to 3 carbon atoms, usually of from 1 to 2 carbon atoms. Halogen substituents may be chlorine, fluorine, or bromine groups, usually 1 to 3, and preferably 2 groups, per indoxyl molecule. As indicated previously, a variety of esters may be employed, which include phosphate, acetate, lactate, sulfate, or the like, or glycosidyl ethers.
Depending upon the purpose of the reaction, various protocols will be employed, as well as various concentrations. For directly measuring an enzyme, the enzyme concentration may be varied widely, depending upon the sample. Usually, the enzyme will be present in from about 0 to 1 μg, more usually from about 0 to 10 ng. In addition, this will vary depending upon whether a peroxidase or hydrolase is involved, with the peroxidase being from about 0.1 pg to 10 ng, while the hydrolase will generally be from about 1 pg to 100 ng.
The benzidine compound will usually be present in about 50 μM to 1 mM, more usually in 100 to 400 μM. The amount of benzidine will be selected so as to be non-rate limiting, so as to provide substantially a Vmax. The indoxyl compound will also be present in non-limiting amounts generally being present in 0.1 to 2 mM.
The inorganic redox couple generally will be at a concentration in the range of about 1.0 to 1000 μM, more usually from about 10 to 200 μM.
The solution will be buffered to optimize substantially the enzymatic activity, generally having a pH in the range of about 4 to 12, more usually from about 5.5 to 10 depending upon the pH optimum of the enzyme with the substrates employed. Various buffers may be employed, which include tris-(hydroxymethyl) methylamine (Tris), phosphate, borate, or the like, usually employing a buffer suitable for the particular enzyme system.
For measuring the enzyme, the various components may be brought together in an appropriately buffered medium in contact with the metal electrode and the rate of change of redox potential in the medium determined.
Where the enzyme is a label, a wide variety of protocols are available. Various assay compositions are commercially available, involving heterogeneous protocols (a separation step) or homogeneous protocols (no separation step). Assay kits are sold which are generally referred to as ELISA or under the trademark EMIT. In performing an ELISA, the medium containing the enzyme conjugate is separated from the enzyme conjugate which has become bound to a support. Modulation of binding of enzyme conjugate is due to a competition between a complementary specific binding pair member bound to a support, and an analyte in solution. Alternatively, in a sandwich assay, the analyte acts as a bridge between a complementary specific binding pair member, which is attached to the support, and the enzyme conjugate. Thereby, the analyte also modulates the binding of enzyme conjugate. Various protocols have appeared in the patent literature and may be exemplified by such patents as U.S. Pat. No. 4,376,110.
For homogeneous enzyme immunoassays, the various reagents may be brought together, where binding of the complementary specific binding pair member to the enzyme conjugate results in a change in enzymatic activity. Thus, in this instance, one need not separate the bound from free enzyme conjugate.
In the heterogeneous assay, the subject reagents may be added to either the surface bound enzyme or to the separated supernatant for determination of enzymatic activity. Enzymatic activity is then monitored with a metal electrode in accordance with the subject invention.
Illustrative of the subject method is the determination of cholesterol, where the cholesterol may be present in a variety of forms, such as HDL, LDL, VLDL or uncomplexed. The cholesterol serves as a substrate for cholesterol oxidase to form hydrogen peroxide, which acts as a substrate for horseradish peroxidase.
The metal electrode may be any type of metal electrode, wire, wafer, grid, or the like. Of particular interest in the subject invention is the use of a metal electrode which is in electrostatic proximity contact with a semiconductor. This device is described in U.S. application Ser. No. 072,196, filed Jul. 10, 1987, whose disclosure is incorporated herein by reference. The apparatus of U.S. Pat. No. 4,591,550 also may be used where such device is modified by affixing to the insulating surface a thin metal film to serve as the metal electrode, so that a plurality of assays may be carried out, where each of the metal electrodes bound to the insulating surface are insulated one from the other. Any means of insulation may be used such as, separating the sample solutions associated with each of the metal electrodes with dividers or using gelled samples which are insulated one from the other, or the like.
The metal electrode will be present on an insulating layer, e.g. silicon oxide or silicon oxynitride with silicon, of about 0.1 to 10 mm thickness. The metal electrode will generally have a surface area of about 0.1 to 5 mm2 and about 0.1 to 1000 μ thickness. The electrode may be electrodeposited or affixed with an adhesive which is stable under the conditions to which it is subjected. For example, the electrode may be 0.5 μ of gold over 300 Angstroms of chromium over 1000 Angstroms of silicon nitride over 300 Angstroms of silicon oxide over n-type silicon. Any surface of the semiconductor which is exposed to the medium will be protected with an insulating coat, e.g. 1000 Angstroms silicon nitride over 100 Angstroms of silicon oxide.
The following examples are offered by way of illustration and not by way of limitation.
Detection of Horseradish Peroxidase
The apparatus employed is described in European patent application Ser. No. 87.305456.3, filed Jun. 19, 1987. The particular construction employed for the following tests is as follows:
The gold layer of about 4.2 mm diameter was placed on a 2.5 mm×5.0 mm rectangular silicon chip which is positioned in a reading chamber containing a platinum controlling electrode and an Ag/AgCl reference electrode. A membrane with the enzyme of interest bound to it or included in it is positioned over the gold electrode and a plastic plunger is pressed against the membrane to restrict diffusion of reagents from the localized environment of the membrane.
The silicon chip is fabricated from a 4-inch diameter wafer of N <100> silicon of approximately 10 to 15 ohm-cm resistivity. The insulator is composed of approximately 340 Angstroms of silicon oxide adjacent to the silicon and overlaid with 1000 Angstroms of silicon nitride deposited by chemical vapor deposition from a reaction of dichlorosilane and ammonia at about 800° C. in a low pressure chamber. The wafers are subsequently annealed in a hydrogen ambient at 1050° C. for 1 hour. The ohmic contact to the silicon chip is made by evaporating approximately 0.5 μ of gold--1% arsenic onto the (bare) etched back surface of a silicon wafer, etching away the gold from regions where light penetration is desired and then alloying the gold into the silicon at 450° C. The sensing gold layer next is deposited over the silicon nitride insulating layer by evaporation in a low pressure chamber of first 300 Angstroms of chromium followed by 5000 Angstroms of gold. The 4.2 mm circles are then formed by protection with a positive photoresist followed by etching first the gold and then the chromium by means of standard metal-etching techniques.
The following reagents were employed:
1) horseradish peroxidase;
2) tetramethylbenzidine (TMB) (20 mg/ml in 95% ethanol);
3) peroxidase buffer: 0.1 M NaAcetate, 1 mM EDTA, 7.5% ethanol, pH 5.5;
4) potassium retro- or ferricyanide, each 100 mM in water.
5) Ruthenium Pentaamine Pyridine Perchlorate, 4.4 mM in water.
A redox solution was-prepared comprising TMB 200 μM, Ruthenium + 2 pentaamine pyridine 25 μM, H2 O2, 250 μM, in peroxidase buffer. Concentrations of horseradish peroxidase on a nitrocellulose support were introduced into the chamber and readings taken by employing a sweep -0.5 to -1.5 volts, gain 16, sweep time 0.4 sec. At 800 pg HRP, the observed result was -3046 μV/s, at 91 pg, -1784 μV/s, at 6 pg, and -327 μV/s at 0 ng. It is evident that by employing the benzidine substrate, TMB, and an inorganic redox couple, ruthenium pentamine pyridine, it is possible to rapidly detect (within 60 secs) -1 pg of HRP, 2.5×10-17 moles of HRP, or 16×106 molecules of HRP.
In the next study, detection of microorganisms was demonstrated. A solution was prepared of N. meningitidis (4×109 cells/ml). A monoclonal antibody-HRP conjugate was prepared and employed in 1:200 dilution in 40% fetal bovine serum (FBS). The membrane filter (polycarbonate) had a 0.2 μm pore 0.2 ml of sample containing varying concentrations of cells was filtered onto the filter followed by incubation with 50 μl of conjugate, after which time the filter was washed 2× with PBS and 1× with NaCl (0.9%)-Tween-20 (0.05%). To the substrate buffer (0.1 M NaAc, 1 mM EDTA, 5% ethanol, pH 5.5, 0.1% Triton X-100) was added: TMB (200 μM); ferrocyanide (100 μM); and hydrogen peroxide (250 μM). Following the procedure described above, the signal was determined for 8×103, 8×104 and 8×105 cells. The observed signal for 8×103 cells was 4.6× the negative signal (-80 μV/s) -369 μV/s, the 8×104 cells' signal was -2231, and the 8×105 cells signal was -10080.
When ferrocene was employed in place of the ferrocyanide at a concentration of 200 μM and 8×103 cells, the ratio was 3.5× neg, while with 800 cells, the ratio was 1.36× neg.
In the next study, ferri-/ferrocyanide was used as the inorganic redox pair in conjunction with TMB.
The reaction solution was 10 μM in potassium ferrocyanide, 0.1 M NaAcetate, pH 5.5, 1 mM EDTA, 0.1% Triton X-100, 5% ethanol, 250 μM hydrogen peroxide, 200 μM TMB.. The HRP conjugate (Lot No. 7-6-87A) was diluted 1:200 in 40% FBS and a N. meningitidis medium (4×109 cells/ml in PBS-Tween-20) was employed. The cell medium (0.2 ml) was filtered through a 0.2 μm pore polycarbonate membrane, followed by contacting the membrane for 10 min with 50 μl of the conjugate, followed by washing once with PBS and once with water. The membrane was then introduced into the measuring compartment. At 800 cells/ml, the observed voltage change (-210 μV/s) was 2.2× negative (-94), and at 8000 cells/ml (-936), 10× negative. Thus, ferrocyanide can be used in a sensitive method for detection of organisms through a redox couple.
In the next study, a Genetran membrane was employed and the analyte was a nucleic acid sample. Genetran is a positively-charged nylon membrane. The membrane was washed using 5% Triton in PBS, pH 7.0, 4×200 μl. Heat denatured single-stranded calf thymus DNA in deionized water (50 μl) was added to the membrane. SSB-HRP conjugate solution (single-stranded DNA binding protein was coupled using maleimide crosslinking chemistry to thiolated HRP) was diluted 1:15,000 in 0.2% BSA, PBS, 0.05% Tween-20, and 300 μl of the solution perfused through the membrane using a peristaltic pump, the filtration requiring 3-4 min. The membrane was then washed 3×200 μl with 5% Triton X-100 in PBS, followed by 3× 200 μl in peroxidase buffer. The membrane was then introduced into a compartment which contained the substrate solution comprising 25 μM of Ru+2 chelate (same as previous example), 200 μM TMB, and 250 μM hydrogen peroxide in the previously described buffer. In the absence of DNA, the voltage change was +262 μV/s, while at 150 pg, the voltage change was -63, at 600 pg, -2474, and at 2500 pg, - 16000. In a repeat of the determination, the negative control gave a voltage change of 150 μV/s, at +150 pg DNA, -312, at 600 pg DNA, -3116, and at 2500 pg DNA, -19268.
Detection of Alkaline Phosphatase
The apparatus employed was a redox sensor, which used a gold spot on silicon water for the metal electrode as described in Example 1. The following reagents were employed:
1) Calf intestinal Alkaline Phosphatase
2) BCIP (5-Bromo-4-chloro-3-indolylphosphate, toluidine salt)
3) Alkaline phosphatase Buffer:
0.2 M Tris (Tris- hydroxymethyl!aminomethane)
1 mM MgCl2, 0.05% NaN3, 0.1% Tween 20, pH 10.0
The assay was based on using alkaline phosphotase as the enzyme, and the hydrolysis of indoxyl phosphate to indoxal. Indoxal is coupled to the inorganic redox component to generate a potentiometric signal.
The procedure employed was to add 10 μl of alkaline phosphatase solution or buffer to 1 ml of substrate containing 1 mM indoxyl phosphate, 1 mM ferricyanide and 0.5 mM ferrocyanide in 0.2 M Tris buffer, 1 mM magnesium acetate, 0.05% sodium azide, pH 10.3. This solution was quickly mixed and added to the measurement compartment. Measurements were made every 0.18 min.
The buffer alone gave a +6.6 μV/s rate. The addition of BSA carrier protein (2%) further increased the background rate to +16 μV/s. Increasing amounts of enzyme were added to the measuring compartment, starting at 7.8 ng/ml as the-concentration in the cell and increasing to 124 ng/ml. The reaction rate, change in potential (μV/s) voltage, was linear in the first 2 minutes of measurement. The reaction rate accelerated as the ferricyanide was consumed, which occurred at the two highest enzyme levels tested, 124 and 250 ng/ml. The reaction rate was proportional to enzyme concentration from 7.8 to 250 ng/ml, a linear regression analysis gave a R2 value of 0.997. An estimate of the sensitivity of the method was conservatively placed at 10 ng/ml. Reduction of the volume of the reaction cell to 0.1 μl should increase the sensitivity to 1 pg of alkaline phosphatase. This represents 8.3×10-18 moles of alkaline phosphatase or approximately 5×106 molecules.
It is evident from the above results, that by using an organic molecule capable of being a substrate for an enzyme and capable of interacting with a metallic redox pair, which in turn can affect the potential of a metal electrode on a semiconductor surface, great sensitivity can be achieved. In particular, hydrogen peroxide and TMB or indoxyl phosphate may be used in conjunction with ferri- ferrocyanide or ruthenium chelates to couple alkaline phosphatase and peroxidase to a metal electrode. These enzymes may be used as labels or in conjunction with other enzymes to measure the presence of specific analytes. Thus, highly sensitive assays for determining a wide variety of analytes and enzymes are obtained which may be carried out rapidly, accurately, with high sensitivity and in very small volumes.
All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.
Claims (17)
1. In a method for determining the presence of an oxidase in an assay medium by employing a metal electrode for detection of a redox reaction, the improvement which comprises:
(a) a tetramethylbenzidine and hydrogen peroxide; with
(b) an iron or ruthenium containing ionic redox couple in the assay medium.
2. A method according to claim 1, wherein said oxidase is horseradish peroxidase and said hydrogen peroxide is produced in said assay medium by the enzymatic reaction of said oxidase with a substrate for the oxidase in said assay medium.
3. A method according to claim 1, wherein said oxidase is horseradish peroxidase and said hydrogen peroxide is produced in the assay medium by a reaction of cholesterol oxidase or glucose oxidase with a substrate for the oxidase.
4. A method according to claim 1, wherein said iron containing ionic redox couple is hexacyanoferrate redox couple.
5. A method according to claim 1, wherein said ruthenium containing ionic redox couple is ruthenium pentamine complex.
6. In a method for determining the presence of peroxidase in an assay medium by employing a metal electrode for detection of a redox reaction, the improvement which comprises:
(a) a benzidine and hydrogen peroxide; with
(b) an ionic redox couple containing an element selected from the group consisting of iron and ruthenium in the assay medium.
7. A method according to claim 6, wherein the metal is a noble metal.
8. A method according to claim 6, wherein the hydrogen peroxide is produced in the assay medium by an enzymatic reaction in the assay medium.
9. In a method for determining the presence of an oxidase in an assay medium by employing a metal electrode for detection of a redox reaction, the improvement which comprises:
(a) a tetramethylbenzidine and hydrogen peroxide, with
(b) an ionic redox couple containing an element selected from the group consisting of iron and ruthenium in the assay medium.
10. A method according to claim 9, wherein the oxidase is horseradish peroxidase and the hydrogen peroxide is produced in the assay medium by an enzymatic reaction in the assay medium during the assay.
11. A method according to claim 9, wherein the oxidase is horseradish peroxidase and the hydrogen peroxide is produced in the assay medium by a reaction of cholesterol oxidase or glucose oxidase with a substrate for the oxidase.
12. A method according to claim 9, wherein the ionic redox couple containing iron is a hexacyanoferrate redox couple.
13. A method according to claim 9, wherein the ionic redox couple containing ruthenium is a ruthenium pentamine pyridine redox couple.
14. In a method for determining the presence of a hydrolase in an assay medium by employing a metal electrode for detection of a redox reaction, the improvement which comprises:
(a) a compound selected from the group consisting of indoxyl ester and other; with
(b) an ionic redox couple containing an element selected from the group consisting of iron and ruthenium in the assay medium.
15. A method according to claim 14, wherein the ionic redox couple containing ruthenium is ruthenium pentamine pyridine redox couple.
16. A method according to claim 14, wherein the ionic redox couple containing iron is a hexacyanoferrate redox couple.
17. A method according to claim 14, wherein the hydrolase is alkaline phosphatase and the indoxyl ester is indoxyl phosphate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/185,730 US5501956A (en) | 1990-03-23 | 1994-01-24 | Polyredox couples in analyte determinations |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49798890A | 1990-03-23 | 1990-03-23 | |
US95246592A | 1992-09-28 | 1992-09-28 | |
US08/185,730 US5501956A (en) | 1990-03-23 | 1994-01-24 | Polyredox couples in analyte determinations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US95246592A Continuation | 1990-03-23 | 1992-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
US5501956A true US5501956A (en) | 1996-03-26 |
Family
ID=27052672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/185,730 Expired - Fee Related US5501956A (en) | 1990-03-23 | 1994-01-24 | Polyredox couples in analyte determinations |
Country Status (1)
Country | Link |
---|---|
US (1) | US5501956A (en) |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5695947A (en) * | 1995-06-06 | 1997-12-09 | Biomedix, Inc. | Amperometric cholesterol biosensor |
US6251260B1 (en) | 1998-08-24 | 2001-06-26 | Therasense, Inc. | Potentiometric sensors for analytic determination |
US6297018B1 (en) | 1998-04-17 | 2001-10-02 | Ljl Biosystems, Inc. | Methods and apparatus for detecting nucleic acid polymorphisms |
US6299757B1 (en) | 1998-10-08 | 2001-10-09 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US20020053523A1 (en) * | 1999-11-04 | 2002-05-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US6591125B1 (en) | 2000-06-27 | 2003-07-08 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US20030127609A1 (en) * | 1998-08-31 | 2003-07-10 | Amer El-Hage | Sample analysis systems |
US6654625B1 (en) | 1999-06-18 | 2003-11-25 | Therasense, Inc. | Mass transport limited in vivo analyte sensor |
US20040096900A1 (en) * | 2000-12-06 | 2004-05-20 | David Laurie | Method for detection of vitamin d metabolites |
US20050003470A1 (en) * | 2003-06-10 | 2005-01-06 | Therasense, Inc. | Glucose measuring device for use in personal area network |
US20050058873A1 (en) * | 2003-09-12 | 2005-03-17 | Arthur Alan R. | Integral fuel cartridge and filter |
US20050227294A1 (en) * | 1997-09-15 | 2005-10-13 | Molecular Devices Corporation | Molecular modification assays involving lipids |
US20060091006A1 (en) * | 1999-11-04 | 2006-05-04 | Yi Wang | Analyte sensor with insertion monitor, and methods |
US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US20060121544A1 (en) * | 1997-09-15 | 2006-06-08 | Annegret Boge | Molecular modification assays |
US7070921B2 (en) | 2000-04-28 | 2006-07-04 | Molecular Devices Corporation | Molecular modification assays |
US20080194990A1 (en) * | 1997-02-06 | 2008-08-14 | Abbott Diabetes Care, Inc. | Integrated Lancing And Measurement Device And Analyte Measuring Methods |
US20090130696A1 (en) * | 2006-05-12 | 2009-05-21 | Lindy Murphy | HDL Cholesterol Sensor Using Selective Surfactant |
US20090188812A1 (en) * | 2006-05-12 | 2009-07-30 | John Morton Broughall | Cholesterol Sensor |
US7587287B2 (en) | 2003-04-04 | 2009-09-08 | Abbott Diabetes Care Inc. | Method and system for transferring analyte test data |
US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US7745142B2 (en) | 1997-09-15 | 2010-06-29 | Molecular Devices Corporation | Molecular modification assays |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US20100213057A1 (en) * | 2009-02-26 | 2010-08-26 | Benjamin Feldman | Self-Powered Analyte Sensor |
US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US7860544B2 (en) | 1998-04-30 | 2010-12-28 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US8149117B2 (en) | 2007-05-08 | 2012-04-03 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US8287454B2 (en) | 1998-04-30 | 2012-10-16 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8612159B2 (en) | 1998-04-30 | 2013-12-17 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8652043B2 (en) | 2001-01-02 | 2014-02-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US8771183B2 (en) | 2004-02-17 | 2014-07-08 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8993331B2 (en) | 2009-08-31 | 2015-03-31 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9226701B2 (en) | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
US9980669B2 (en) | 2011-11-07 | 2018-05-29 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US10117614B2 (en) | 2006-02-28 | 2018-11-06 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US11793936B2 (en) | 2009-05-29 | 2023-10-24 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4385114A (en) * | 1974-12-21 | 1983-05-24 | Boehringer Mannheim Gmbh | Oxidation indicators comprising 3,3',5,5'-tetraalkylbenzidine compounds |
US4591550A (en) * | 1984-03-01 | 1986-05-27 | Molecular Devices Corporation | Device having photoresponsive electrode for determining analytes including ligands and antibodies |
US4942127A (en) * | 1988-05-06 | 1990-07-17 | Molecular Devices Corporation | Polyredox couples in analyte determinations |
-
1994
- 1994-01-24 US US08/185,730 patent/US5501956A/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4385114A (en) * | 1974-12-21 | 1983-05-24 | Boehringer Mannheim Gmbh | Oxidation indicators comprising 3,3',5,5'-tetraalkylbenzidine compounds |
US4591550A (en) * | 1984-03-01 | 1986-05-27 | Molecular Devices Corporation | Device having photoresponsive electrode for determining analytes including ligands and antibodies |
US4942127A (en) * | 1988-05-06 | 1990-07-17 | Molecular Devices Corporation | Polyredox couples in analyte determinations |
Cited By (277)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5695947A (en) * | 1995-06-06 | 1997-12-09 | Biomedix, Inc. | Amperometric cholesterol biosensor |
US20090078586A1 (en) * | 1997-02-06 | 2009-03-26 | Therasense, Inc. | Small Volume In Vitro Analyte Sensor |
US20080277293A1 (en) * | 1997-02-06 | 2008-11-13 | Therasense, Inc. | Small Volume In Vitro Analyte Sensor |
US8114270B2 (en) | 1997-02-06 | 2012-02-14 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US8123929B2 (en) | 1997-02-06 | 2012-02-28 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US9234864B2 (en) | 1997-02-06 | 2016-01-12 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US8105476B2 (en) | 1997-02-06 | 2012-01-31 | Abbott Diabetes Care Inc. | Integrated lancing and measurement device |
US8142642B2 (en) | 1997-02-06 | 2012-03-27 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US8142643B2 (en) | 1997-02-06 | 2012-03-27 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US7988845B2 (en) | 1997-02-06 | 2011-08-02 | Abbott Diabetes Care Inc. | Integrated lancing and measurement device and analyte measuring methods |
US7909984B2 (en) | 1997-02-06 | 2011-03-22 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US7906009B2 (en) | 1997-02-06 | 2011-03-15 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US20080194990A1 (en) * | 1997-02-06 | 2008-08-14 | Abbott Diabetes Care, Inc. | Integrated Lancing And Measurement Device And Analyte Measuring Methods |
US20080277291A1 (en) * | 1997-02-06 | 2008-11-13 | Therasense, Inc. | Small Volume In Vitro Analyte Sensor |
US20100012510A1 (en) * | 1997-02-06 | 2010-01-21 | Adam Heller | Small Volume In Vitro Analyte Sensor |
US20090002683A1 (en) * | 1997-02-06 | 2009-01-01 | Adam Heller | Small Volume in Vitro Analyte Sensor |
US8114271B2 (en) | 1997-02-06 | 2012-02-14 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US8808531B2 (en) | 1997-02-06 | 2014-08-19 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US20090000961A1 (en) * | 1997-02-06 | 2009-01-01 | Adam Heller | Small Volume in Vitro Analyte Sensor |
US8118992B2 (en) | 1997-02-06 | 2012-02-21 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US20060121544A1 (en) * | 1997-09-15 | 2006-06-08 | Annegret Boge | Molecular modification assays |
US7745142B2 (en) | 1997-09-15 | 2010-06-29 | Molecular Devices Corporation | Molecular modification assays |
US7632651B2 (en) | 1997-09-15 | 2009-12-15 | Mds Analytical Technologies (Us) Inc. | Molecular modification assays |
US20100304404A1 (en) * | 1997-09-15 | 2010-12-02 | Annegret Boge | Molecular modification assays |
US20050227294A1 (en) * | 1997-09-15 | 2005-10-13 | Molecular Devices Corporation | Molecular modification assays involving lipids |
US6297018B1 (en) | 1998-04-17 | 2001-10-02 | Ljl Biosystems, Inc. | Methods and apparatus for detecting nucleic acid polymorphisms |
US8473021B2 (en) | 1998-04-30 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10478108B2 (en) | 1998-04-30 | 2019-11-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8660627B2 (en) | 1998-04-30 | 2014-02-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8649841B2 (en) | 1998-04-30 | 2014-02-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8641619B2 (en) | 1998-04-30 | 2014-02-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8670815B2 (en) | 1998-04-30 | 2014-03-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8622906B2 (en) | 1998-04-30 | 2014-01-07 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8617071B2 (en) | 1998-04-30 | 2013-12-31 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8612159B2 (en) | 1998-04-30 | 2013-12-17 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8597189B2 (en) | 1998-04-30 | 2013-12-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8672844B2 (en) | 1998-04-30 | 2014-03-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8734348B2 (en) | 1998-04-30 | 2014-05-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8738109B2 (en) | 1998-04-30 | 2014-05-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8734346B2 (en) | 1998-04-30 | 2014-05-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8744545B2 (en) | 1998-04-30 | 2014-06-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8774887B2 (en) | 1998-04-30 | 2014-07-08 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8409131B2 (en) | 1998-04-30 | 2013-04-02 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8391945B2 (en) | 1998-04-30 | 2013-03-05 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8380273B2 (en) | 1998-04-30 | 2013-02-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8840553B2 (en) | 1998-04-30 | 2014-09-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8372005B2 (en) | 1998-04-30 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8366614B2 (en) | 1998-04-30 | 2013-02-05 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8357091B2 (en) | 1998-04-30 | 2013-01-22 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8353829B2 (en) | 1998-04-30 | 2013-01-15 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346336B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8880137B2 (en) | 1998-04-30 | 2014-11-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8666469B2 (en) | 1998-04-30 | 2014-03-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8306598B2 (en) | 1998-04-30 | 2012-11-06 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8287454B2 (en) | 1998-04-30 | 2012-10-16 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9014773B2 (en) | 1998-04-30 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8275439B2 (en) | 1998-04-30 | 2012-09-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8273022B2 (en) | 1998-04-30 | 2012-09-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8265726B2 (en) | 1998-04-30 | 2012-09-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8260392B2 (en) | 1998-04-30 | 2012-09-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8255031B2 (en) | 1998-04-30 | 2012-08-28 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9011331B2 (en) | 1998-04-30 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7860544B2 (en) | 1998-04-30 | 2010-12-28 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7869853B1 (en) | 1998-04-30 | 2011-01-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7885699B2 (en) | 1998-04-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9326714B2 (en) | 1998-04-30 | 2016-05-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9042953B2 (en) | 1998-04-30 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8235896B2 (en) | 1998-04-30 | 2012-08-07 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8231532B2 (en) | 1998-04-30 | 2012-07-31 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8226555B2 (en) | 1998-04-30 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066697B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8226557B2 (en) | 1998-04-30 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8226558B2 (en) | 1998-04-30 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8224413B2 (en) | 1998-04-30 | 2012-07-17 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8177716B2 (en) | 1998-04-30 | 2012-05-15 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8175673B2 (en) | 1998-04-30 | 2012-05-08 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8162829B2 (en) | 1998-04-30 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066694B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9072477B2 (en) | 1998-04-30 | 2015-07-07 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6251260B1 (en) | 1998-08-24 | 2001-06-26 | Therasense, Inc. | Potentiometric sensors for analytic determination |
US20030127609A1 (en) * | 1998-08-31 | 2003-07-10 | Amer El-Hage | Sample analysis systems |
US6982431B2 (en) | 1998-08-31 | 2006-01-03 | Molecular Devices Corporation | Sample analysis systems |
US8372261B2 (en) | 1998-10-08 | 2013-02-12 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US20100018870A1 (en) * | 1998-10-08 | 2010-01-28 | Feldman Benjamin J | Small Volume In Vitro Sensor and Methods of Making |
US6299757B1 (en) | 1998-10-08 | 2001-10-09 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US9891185B2 (en) | 1998-10-08 | 2018-02-13 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US20050278945A1 (en) * | 1998-10-08 | 2005-12-22 | Therasense, Inc. | Small volume in vitro analyte sensor |
US8091220B2 (en) | 1998-10-08 | 2012-01-10 | Abbott Diabetes Care Inc. | Methods of making small volume in vitro analyte sensors |
US8650751B2 (en) | 1998-10-08 | 2014-02-18 | Abbott Diabetes Care Inc. | Methods of making small volume in vitro analyte sensors |
US8153063B2 (en) | 1998-10-08 | 2012-04-10 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8163164B2 (en) | 1998-10-08 | 2012-04-24 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8087162B2 (en) | 1998-10-08 | 2012-01-03 | Abbott Diabetes Care Inc. | Methods of making small volume in vitro analyte sensors |
US8083928B2 (en) | 1998-10-08 | 2011-12-27 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8083929B2 (en) | 1998-10-08 | 2011-12-27 | Abbott Diabetes Care Inc. | Small volume in vitro sensor and methods of making |
US8182670B2 (en) | 1998-10-08 | 2012-05-22 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8182671B2 (en) | 1998-10-08 | 2012-05-22 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8187895B2 (en) | 1998-10-08 | 2012-05-29 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8186044B2 (en) | 1998-10-08 | 2012-05-29 | Abbott Diabetes Care Inc. | Method of manufacturing small volume in vitro analyte sensors |
US7058437B2 (en) | 1998-10-08 | 2006-06-06 | Therasense, Inc. | Methods of determining concentration of glucose |
US8192611B2 (en) | 1998-10-08 | 2012-06-05 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8211363B2 (en) | 1998-10-08 | 2012-07-03 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8083924B2 (en) | 1998-10-08 | 2011-12-27 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8221685B2 (en) | 1998-10-08 | 2012-07-17 | Abbott Diabetes Care Inc. | Small volume in vitro sensor and methods of making |
US8118993B2 (en) | 1998-10-08 | 2012-02-21 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US9341591B2 (en) | 1998-10-08 | 2016-05-17 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US8226815B2 (en) | 1998-10-08 | 2012-07-24 | Abbott Diabetes Care Inc. | Small volume in vitro sensor and methods of making |
US8701282B2 (en) | 1998-10-08 | 2014-04-22 | Abbott Diabetes Care Inc. | Method for manufacturing a biosensor |
US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US9316609B2 (en) | 1998-10-08 | 2016-04-19 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US9291592B2 (en) | 1998-10-08 | 2016-03-22 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US7225535B2 (en) | 1998-10-08 | 2007-06-05 | Abbott Diabetes Care, Inc. | Method of manufacturing electrochemical sensors |
US8728297B2 (en) | 1998-10-08 | 2014-05-20 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US20100243478A1 (en) * | 1998-10-08 | 2010-09-30 | Feldman Benjamin J | Small Volume In Vitro Analyte Sensor and Methods of Making |
US9234863B2 (en) | 1998-10-08 | 2016-01-12 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US8262996B2 (en) | 1998-10-08 | 2012-09-11 | Abbott Diabetes Care Inc. | Small volume in vitro sensor and methods of making |
US20040060818A1 (en) * | 1998-10-08 | 2004-04-01 | Therasense, Inc. | Small volume in vitro analyte sensor and methods of making |
US8268144B2 (en) | 1998-10-08 | 2012-09-18 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8268163B2 (en) | 1998-10-08 | 2012-09-18 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US6461496B1 (en) | 1998-10-08 | 2002-10-08 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US20040054267A1 (en) * | 1998-10-08 | 2004-03-18 | Therasense, Inc. | Small volume in vitro analyte sensor |
US8273241B2 (en) | 1998-10-08 | 2012-09-25 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8272125B2 (en) | 1998-10-08 | 2012-09-25 | Abbott Diabetes Care Inc. | Method of manufacturing in vitro analyte sensors |
US20100081907A1 (en) * | 1998-10-08 | 2010-04-01 | Feldman Benjamin J | Small Volume In Vitro Analyte Sensor and Methods of Making |
US20090014328A1 (en) * | 1998-10-08 | 2009-01-15 | Abbott Diabetes Care Inc. | Small Volume in vitro Analyte Sensor and Methods of Making |
US20100018877A1 (en) * | 1998-10-08 | 2010-01-28 | Feldman Benjamin J | Small Volume In Vitro Sensor and Methods of Making |
US20030199744A1 (en) * | 1998-10-08 | 2003-10-23 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6618934B1 (en) | 1998-10-08 | 2003-09-16 | Therasense, Inc. | Method of manufacturing small volume in vitro analyte sensor |
US8449758B2 (en) | 1998-10-08 | 2013-05-28 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8425743B2 (en) | 1998-10-08 | 2013-04-23 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US8425758B2 (en) | 1998-10-08 | 2013-04-23 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US6592745B1 (en) | 1998-10-08 | 2003-07-15 | Therasense, Inc. | Method of using a small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US7550069B2 (en) | 1998-10-08 | 2009-06-23 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US7563350B2 (en) | 1998-10-08 | 2009-07-21 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor |
US8377378B2 (en) | 1998-10-08 | 2013-02-19 | Abbott Diabetes Care Inc. | Small volume in vitro analyte sensor and methods of making |
US6654625B1 (en) | 1999-06-18 | 2003-11-25 | Therasense, Inc. | Mass transport limited in vivo analyte sensor |
US6975893B2 (en) | 1999-06-18 | 2005-12-13 | Therasense, Inc. | Mass transport limited in vivo analyte sensor |
US20040225230A1 (en) * | 1999-11-04 | 2004-11-11 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US6942518B2 (en) | 1999-11-04 | 2005-09-13 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US6616819B1 (en) | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US20090260986A1 (en) * | 1999-11-04 | 2009-10-22 | Abbott Diabetes Care Inc. | Analyte sensor with insertion monitor, and methods |
US8066858B2 (en) | 1999-11-04 | 2011-11-29 | Abbott Diabetes Care Inc. | Analyte sensor with insertion monitor, and methods |
US20020157948A2 (en) * | 1999-11-04 | 2002-10-31 | Therasense, Inc. | Small Volume in Vitro Analyte Sensor and Methods |
US20080021295A1 (en) * | 1999-11-04 | 2008-01-24 | Yi Wang | Sample Acquisition and Analyte Measurement Device |
US20020053523A1 (en) * | 1999-11-04 | 2002-05-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US20020148739A2 (en) * | 1999-11-04 | 2002-10-17 | Therasense, Inc. | Small Volume in Vitro Analyte Sensor and Methods |
US20080283396A1 (en) * | 1999-11-04 | 2008-11-20 | Abbot Diabetes Care, Inc. | Analyte Sensor with Insertion Monitor, and Methods |
US6749740B2 (en) | 1999-11-04 | 2004-06-15 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US20060091006A1 (en) * | 1999-11-04 | 2006-05-04 | Yi Wang | Analyte sensor with insertion monitor, and methods |
US20090260985A1 (en) * | 1999-11-04 | 2009-10-22 | Abbott Diabetes Care Inc. | Analyte sensor with insertion monitor, and methods |
US20020084196A1 (en) * | 1999-11-04 | 2002-07-04 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US7070921B2 (en) | 2000-04-28 | 2006-07-04 | Molecular Devices Corporation | Molecular modification assays |
US9017259B2 (en) | 2000-06-27 | 2015-04-28 | Abbott Diabetes Care Inc. | Integrated sample acquisition and analyte measurement device |
US6591125B1 (en) | 2000-06-27 | 2003-07-08 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US8795176B2 (en) | 2000-06-27 | 2014-08-05 | Abbott Diabetes Care Inc. | Integrated sample acquisition and analyte measurement device |
US20080027302A1 (en) * | 2000-06-27 | 2008-01-31 | Therasense, Inc. | Integrated Sample Acquisition and Analyte Measurement Device |
US8532731B2 (en) | 2000-06-27 | 2013-09-10 | Abbott Diabetes Care Inc. | Methods of determining analyte concentration |
US9662057B2 (en) | 2000-06-27 | 2017-05-30 | Abbott Diabetes Care Inc. | Integrated sample acquisition and analyte measurement method |
US9271669B2 (en) | 2000-06-27 | 2016-03-01 | Abbott Diabetes Care Inc. | Method for integrated sample acquisition and analyte measurement device |
US20090270764A1 (en) * | 2000-06-27 | 2009-10-29 | Abbott Diabetes Care Inc. | Methods of determining concentration of ketone bodies |
US7482162B2 (en) * | 2000-12-06 | 2009-01-27 | Immunodiagnostic Systems Ltd. | Determination of vitamin D metabolite and displacement from plasma or serum binding proteins |
US20040096900A1 (en) * | 2000-12-06 | 2004-05-20 | David Laurie | Method for detection of vitamin d metabolites |
US9498159B2 (en) | 2001-01-02 | 2016-11-22 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9610034B2 (en) | 2001-01-02 | 2017-04-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8652043B2 (en) | 2001-01-02 | 2014-02-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8668645B2 (en) | 2001-01-02 | 2014-03-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9011332B2 (en) | 2001-01-02 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9477811B2 (en) | 2001-04-02 | 2016-10-25 | Abbott Diabetes Care Inc. | Blood glucose tracking apparatus and methods |
US8765059B2 (en) | 2001-04-02 | 2014-07-01 | Abbott Diabetes Care Inc. | Blood glucose tracking apparatus |
US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US8268243B2 (en) | 2001-04-02 | 2012-09-18 | Abbott Diabetes Care Inc. | Blood glucose tracking apparatus and methods |
US8236242B2 (en) | 2001-04-02 | 2012-08-07 | Abbott Diabetes Care Inc. | Blood glucose tracking apparatus and methods |
US7976778B2 (en) | 2001-04-02 | 2011-07-12 | Abbott Diabetes Care Inc. | Blood glucose tracking apparatus |
US8187183B2 (en) | 2002-12-31 | 2012-05-29 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US8622903B2 (en) | 2002-12-31 | 2014-01-07 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US10750952B2 (en) | 2002-12-31 | 2020-08-25 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US10039881B2 (en) | 2002-12-31 | 2018-08-07 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US9962091B2 (en) | 2002-12-31 | 2018-05-08 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US8560250B2 (en) | 2003-04-04 | 2013-10-15 | Abbott Laboratories | Method and system for transferring analyte test data |
US8437966B2 (en) | 2003-04-04 | 2013-05-07 | Abbott Diabetes Care Inc. | Method and system for transferring analyte test data |
US8483974B2 (en) | 2003-04-04 | 2013-07-09 | Abbott Diabetes Care Inc. | Method and system for transferring analyte test data |
US8682598B2 (en) | 2003-04-04 | 2014-03-25 | Abbott Laboratories | Method and system for transferring analyte test data |
US7587287B2 (en) | 2003-04-04 | 2009-09-08 | Abbott Diabetes Care Inc. | Method and system for transferring analyte test data |
US9730584B2 (en) | 2003-06-10 | 2017-08-15 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US8512239B2 (en) | 2003-06-10 | 2013-08-20 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US8647269B2 (en) | 2003-06-10 | 2014-02-11 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US20050003470A1 (en) * | 2003-06-10 | 2005-01-06 | Therasense, Inc. | Glucose measuring device for use in personal area network |
US20050058873A1 (en) * | 2003-09-12 | 2005-03-17 | Arthur Alan R. | Integral fuel cartridge and filter |
US8771183B2 (en) | 2004-02-17 | 2014-07-08 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
US10231654B2 (en) | 2005-11-01 | 2019-03-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11911151B1 (en) | 2005-11-01 | 2024-02-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10952652B2 (en) | 2005-11-01 | 2021-03-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11103165B2 (en) | 2005-11-01 | 2021-08-31 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11272867B2 (en) | 2005-11-01 | 2022-03-15 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9326716B2 (en) | 2005-11-01 | 2016-05-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11363975B2 (en) | 2005-11-01 | 2022-06-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10201301B2 (en) | 2005-11-01 | 2019-02-12 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11399748B2 (en) | 2005-11-01 | 2022-08-02 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8915850B2 (en) | 2005-11-01 | 2014-12-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8920319B2 (en) | 2005-11-01 | 2014-12-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9078607B2 (en) | 2005-11-01 | 2015-07-14 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9323898B2 (en) | 2005-11-04 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US11538580B2 (en) | 2005-11-04 | 2022-12-27 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US9669162B2 (en) | 2005-11-04 | 2017-06-06 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US8585591B2 (en) | 2005-11-04 | 2013-11-19 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US10117614B2 (en) | 2006-02-28 | 2018-11-06 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US8597575B2 (en) | 2006-03-31 | 2013-12-03 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US9380971B2 (en) | 2006-03-31 | 2016-07-05 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US8593109B2 (en) | 2006-03-31 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US9039975B2 (en) | 2006-03-31 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US9625413B2 (en) | 2006-03-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US9743863B2 (en) | 2006-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US8933664B2 (en) | 2006-03-31 | 2015-01-13 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US20090188812A1 (en) * | 2006-05-12 | 2009-07-30 | John Morton Broughall | Cholesterol Sensor |
US20090130696A1 (en) * | 2006-05-12 | 2009-05-21 | Lindy Murphy | HDL Cholesterol Sensor Using Selective Surfactant |
US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US12040067B2 (en) | 2007-02-18 | 2024-07-16 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US9801545B2 (en) | 2007-03-01 | 2017-10-31 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US9095290B2 (en) | 2007-03-01 | 2015-08-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9649057B2 (en) | 2007-05-08 | 2017-05-16 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US10952611B2 (en) | 2007-05-08 | 2021-03-23 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8149117B2 (en) | 2007-05-08 | 2012-04-03 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9574914B2 (en) | 2007-05-08 | 2017-02-21 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9000929B2 (en) | 2007-05-08 | 2015-04-07 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9035767B2 (en) | 2007-05-08 | 2015-05-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8362904B2 (en) | 2007-05-08 | 2013-01-29 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9949678B2 (en) | 2007-05-08 | 2018-04-24 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US8593287B2 (en) | 2007-05-08 | 2013-11-26 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US10653317B2 (en) | 2007-05-08 | 2020-05-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9314198B2 (en) | 2007-05-08 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US11696684B2 (en) | 2007-05-08 | 2023-07-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US9177456B2 (en) | 2007-05-08 | 2015-11-03 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US10178954B2 (en) | 2007-05-08 | 2019-01-15 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US8473220B2 (en) | 2009-01-29 | 2013-06-25 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US9066709B2 (en) | 2009-01-29 | 2015-06-30 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US8676513B2 (en) | 2009-01-29 | 2014-03-18 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US9668684B2 (en) | 2009-02-26 | 2017-06-06 | Abbott Diabetes Care Inc. | Self-powered analyte sensor |
US10631768B2 (en) | 2009-02-26 | 2020-04-28 | Abbott Diabetes Inc. | Self-powered analyte sensor |
US20100213057A1 (en) * | 2009-02-26 | 2010-08-26 | Benjamin Feldman | Self-Powered Analyte Sensor |
US20100213082A1 (en) * | 2009-02-26 | 2010-08-26 | Benjamin Feldman | Self-Powered Analyte Sensor |
US9226701B2 (en) | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
US11793936B2 (en) | 2009-05-29 | 2023-10-24 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US11872370B2 (en) | 2009-05-29 | 2024-01-16 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US11150145B2 (en) | 2009-08-31 | 2021-10-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US10429250B2 (en) | 2009-08-31 | 2019-10-01 | Abbott Diabetes Care, Inc. | Analyte monitoring system and methods for managing power and noise |
US12279894B2 (en) | 2009-08-31 | 2025-04-22 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US11635332B2 (en) | 2009-08-31 | 2023-04-25 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US9968302B2 (en) | 2009-08-31 | 2018-05-15 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US8993331B2 (en) | 2009-08-31 | 2015-03-31 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
US11045147B2 (en) | 2009-08-31 | 2021-06-29 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US9750439B2 (en) | 2009-09-29 | 2017-09-05 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US10349874B2 (en) | 2009-09-29 | 2019-07-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US9980669B2 (en) | 2011-11-07 | 2018-05-29 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US11950936B2 (en) | 2012-09-17 | 2024-04-09 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
US11612363B2 (en) | 2012-09-17 | 2023-03-28 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5501956A (en) | Polyredox couples in analyte determinations | |
US4942127A (en) | Polyredox couples in analyte determinations | |
US4963245A (en) | Unitary multiple electrode sensor | |
US5427912A (en) | Electrochemical enzymatic complementation immunoassay | |
Wright et al. | Specific binding assay for biotin based on enzyme channelling with direct electron transfer electrochemical detection using horseradish peroxidase | |
Skládal | Advances in electrochemical immunosensors | |
JP3387926B2 (en) | Potentiometric biosensor and method of using the same | |
US5981203A (en) | Unitary sandwich enzyme immunoassay cassette, device and method of use | |
KR101532064B1 (en) | Electrochemical analyte detection apparatus and method | |
EP0368474B1 (en) | Enhanced amperometric sensor | |
US6416641B1 (en) | Biosensor | |
US6444115B1 (en) | Electrochemical method for measuring chemical reaction rates | |
Soldatkin et al. | Creatinine sensitive biosensor based on ISFETs and creatinine deiminase immobilised in BSA membrane | |
Kukla et al. | Multienzyme electrochemical sensor array for determination of heavy metal ions | |
EP0859230A1 (en) | Detection of analytes using electrochemistry | |
MXPA94006538A (en) | Immunoassayo de complementacion enzimaticaelectroquim | |
JPS62294958A (en) | Assay method | |
Dutta et al. | An ultrasensitive enzyme-free electrochemical immunosensor based on redox cycling amplification using methylene blue | |
US6214612B1 (en) | Cholesterol sensor containing electrodes, cholesterol dehydrogenase, nicotinamide adenine dinucleotide and oxidized electron mediator | |
JPS6123957A (en) | Detection and discrimination of optical responding redox | |
Hart et al. | Studies towards a disposable screen-printed amperometric biosensor for progesterone | |
JPH10185860A (en) | Biosensor | |
CA2130947C (en) | Dry elements, test devices, test kits and methods for chemiluminescent detection of analytes using peroxidase-labeled reagents | |
Ivnitski et al. | An amperometric biosensor for real-time analysis of molecular recognition | |
Situmorang et al. | Flow injection potentiometry for enzymatic assay of cholesterol with a tungsten electrode sensor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20000326 |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |